Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Bacon

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Journal of Hepatology|April 22, 2014
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Gastroenterology|April 15, 2014
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosisMichael P Manns, John M Vierling, Bruce R Bacon, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Journal of Hepatology|April 22, 2014
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Gastroenterology|April 15, 2014
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosisMichael P Manns, John M Vierling, Bruce R Bacon, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Pageof 12